| 0.01 0 (0%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.38 | 1-year : | 0.61 |
| Resists | First : | 0.33 | Second : | 0.52 |
| Pivot price | 0.12 |
|||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0.01 |
MA(20) : | 0.16 |
| MA(100) : | 0.98 |
MA(250) : | 1.64 |
|
| MACD | MACD : | -0.2  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 1.2 |
D(3) : | 2.1 |
| RSI | RSI(14): 28.8 |
|||
| 52-week | High : | 4.13 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIMI ] has closed above bottom band by 30.6%. Bollinger Bands are 7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.02 - 0.02 | 0.02 - 0.02 |
| Low: | 0.01 - 0.01 | 0.01 - 0.01 |
| Close: | 0.01 - 0.01 | 0.01 - 0.01 |
BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes generic drugs, Chinese herbal medicine, biochemical drugs, raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, health foods, sundry products, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is based in Chongqing, the People's Republic of China.
Wed, 21 Aug 2024
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - Yahoo Finance
Tue, 30 Jul 2024
BIMI Stock Touches 52-Week Low at $1 Amid Market Challenges - Investing.com
Mon, 29 Jul 2024
BIMI Holdings faces Nasdaq delisting over compliance issues - Investing.com
Mon, 20 May 2024
BIMI Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq - StockTitan
Wed, 03 Apr 2024
With A 60% Price Drop For BIMI Holdings Inc. (NASDAQ:BIMI) You'll Still Get What You Pay For - Simply Wall St
Fri, 22 Sep 2023
BIMI International Medical’s Phenix Bio appoints Hao Mu as distributor - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Pharmaceuticals
|
|
| Shares Out | 14 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 93.5 (%) |
| Held by Institutions | 0.4 (%) |
| Shares Short | 153 (K) |
| Shares Short P.Month | 17 (K) |
| EPS | -6.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.29 |
| Profit Margin | -83.2 % |
| Operating Margin | -124.9 % |
| Return on Assets (ttm) | -13.1 % |
| Return on Equity (ttm) | -103.8 % |
| Qtrly Rev. Growth | -48.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -0.49 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.01 |
| Price to Cash Flow | -0.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|